- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05866952
Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC VQ)
July 6, 2023 updated by: Tufts Medical Center
Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations
Study Overview
Status
Enrolling by invitation
Intervention / Treatment
Detailed Description
This is a study to describe the overall pattern of lung ventilation and perfusion defects in individuals with PASC.
Subjects with PASC with a documented history of COVID-19 and persistent symptoms of fatigue, dyspnea, and/or exercise intolerance will complete questionnaires, and undergo pulmonary function tests, 6-minute walk tests, and a low dose CT chest to describe the overall pattern of lung regional ventilation and blood distribution and to compare this pattern to asymptomatic controls with and without prior COVID-19.
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bipin Malla
- Phone Number: 617-636-6304
- Email: tuftsmccorstudy@tuftsmedicalcenter.org
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The primary population of interest includes participants with a history of COVID-19 who continue to have symptoms of dyspnea, fatigue, or exercise intolerance 3 months beyond their initial infection.
The comparison cohorts will include 2 controls: individuals fully recovered from prior COVID-19 and healthy controls without a history of COVID-19.
Description
Inclusion Criteria:
- Age ≥ 18
- Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing > 3 months ago or no previous history of SARS-CoV-2 infection (control group only)
- Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs)
- New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)
Exclusion Criteria:
- SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months
- Inability to provide consent or non-English speaking
- Pregnancy
- Any respiratory infection in last 4 weeks
- PFT relative contraindications
- History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism
- Active malignancy undergoing treatment or history of malignancy involving the lung
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Post-Acute Sequelae of SARS-CoV-2 (PASC) Group
Subjects with PASC with a documented history of COVID-19 and persistent symptoms of fatigue, dyspnea, and/or exercise intolerance
|
Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
|
Control: Fully recovered COVID-19
Subjects with a history of COVID-19 who have fully recovered from COVID-19 with no post-acute sequelae of SARS-Cov-2
|
Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
|
Control: No history of COVID-19
Healthy subjects without a documented history of COVID-19, no current symptoms, and a normal baseline High resolution CT of the chest
|
Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measures of regional lung ventilation
Time Frame: 1 day
|
1 day
|
Measures of blood volume distribution
Time Frame: 1 day
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dyspnea severity scores
Time Frame: 1 day
|
1 day
|
Fatigue severity scores
Time Frame: 1 day
|
1 day
|
Quality of life scores
Time Frame: 1 day
|
1 day
|
Six-minute walk distance
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2023
Primary Completion (Estimated)
May 31, 2024
Study Completion (Estimated)
May 31, 2024
Study Registration Dates
First Submitted
May 16, 2023
First Submitted That Met QC Criteria
May 18, 2023
First Posted (Actual)
May 19, 2023
Study Record Updates
Last Update Posted (Actual)
July 10, 2023
Last Update Submitted That Met QC Criteria
July 6, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Signs and Symptoms, Respiratory
- Encephalomyelitis
- Chronic Disease
- Neuroinflammatory Diseases
- Post-Infectious Disorders
- COVID-19
- Fatigue Syndrome, Chronic
- Dyspnea
- Post-Acute COVID-19 Syndrome
Other Study ID Numbers
- 2337
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea Invasive Mechanical Ventilation-associatedFrance
-
Mayo ClinicCompletedShortness of Breath | Cardiac; DyspneaUnited States
-
Qure Healthcare, LLCJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedDyspnea | Unexplained Chronic DyspneaUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedRelationship Between Dyspnea and Ventilatory VariabilityFrance
-
University of MonastirCompleted
-
University of California, Los AngelesNot yet recruitingShortness of Breath/Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea and Respiratory Insufficiency in ChildrenFrance
-
Medical University of ViennaRecruitingEchocardiography | Acute DyspneaAustria
-
Intersection Medical, Inc.CompletedPulmonary Congestion | Dyspnea, | Acute Heart Failure SyndromeUnited States
-
University of MonastirCompletedDyspnea; CardiacTunisia
Clinical Trials on Computed Tomography of the Chest
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, France; Ministère de la Santé et des SolidaritésRecruitingLung Cancer ScreeningFrance
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States
-
University of MilanCompletedPneumonia | Bronchiectasis | Chronic Obstructive Pulmonary Disease | Lung Cancer | Tuberculosis | Acute Bronchitis | Cryptogenic HaemoptysisItaly
-
Al-Azhar UniversityAin Shams University; South Valley University; Helwan University; National Liver...Completed
-
Policlinico HospitalCompletedARDS: Acute Respiratory Distress SyndromeItaly
-
Menoufia UniversityCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RecruitingPulmonary NoduleUnited States
-
Seoul National University Bundang HospitalCompletedCardiopulmonary Resuscitation | Hand Position
-
Jena University HospitalCompletedSevere Acute Respiratory Syndrome Coronavirus 2Germany